JP2018505158A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018505158A5 JP2018505158A5 JP2017536879A JP2017536879A JP2018505158A5 JP 2018505158 A5 JP2018505158 A5 JP 2018505158A5 JP 2017536879 A JP2017536879 A JP 2017536879A JP 2017536879 A JP2017536879 A JP 2017536879A JP 2018505158 A5 JP2018505158 A5 JP 2018505158A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- odd
- chain fatty
- fatty acids
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 235000014113 dietary fatty acids Nutrition 0.000 claims 13
- 239000000194 fatty acid Substances 0.000 claims 13
- 150000004665 fatty acids Chemical class 0.000 claims 13
- 210000002966 Serum Anatomy 0.000 claims 7
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 5
- 210000003617 Erythrocyte Membrane Anatomy 0.000 claims 3
- 102000008857 Ferritin Human genes 0.000 claims 3
- 108050000784 Ferritin Proteins 0.000 claims 3
- 238000008416 Ferritin Methods 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 206010062060 Hyperlipidaemia Diseases 0.000 claims 2
- 206010065973 Iron overload Diseases 0.000 claims 2
- 230000036772 blood pressure Effects 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 150000003626 triacylglycerols Chemical class 0.000 claims 2
- 102100000648 ATM Human genes 0.000 claims 1
- 108060006202 ATM Proteins 0.000 claims 1
- 208000004611 Abdominal Obesity Diseases 0.000 claims 1
- 102000011690 Adiponectin Human genes 0.000 claims 1
- 108010076365 Adiponectin Proteins 0.000 claims 1
- 208000006673 Asthma Diseases 0.000 claims 1
- 102000025380 C-Reactive Protein Human genes 0.000 claims 1
- 108010074051 C-Reactive Protein Proteins 0.000 claims 1
- 102100015724 CRP Human genes 0.000 claims 1
- 208000008787 Cardiovascular Disease Diseases 0.000 claims 1
- 206010065941 Central obesity Diseases 0.000 claims 1
- 102000000018 Chemokine CCL2 Human genes 0.000 claims 1
- 108010055292 Chemokine CCL2 Proteins 0.000 claims 1
- 229940107161 Cholesterol Drugs 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 108060003412 GRP Proteins 0.000 claims 1
- 102000015779 HDL Lipoproteins Human genes 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- KEMQGTRYUADPNZ-UHFFFAOYSA-N Heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 claims 1
- 210000002381 Plasma Anatomy 0.000 claims 1
- 230000037165 Serum Concentration Effects 0.000 claims 1
- 206010040984 Sleep disease Diseases 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims 1
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 claims 1
- 108091006318 cAMP receptor protein Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000001883 cholelithiasis Diseases 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 235000020828 fasting Nutrition 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000000051 modifying Effects 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- 238000002203 pretreatment Methods 0.000 claims 1
- 230000000770 pro-inflamatory Effects 0.000 claims 1
- 230000000069 prophylaxis Effects 0.000 claims 1
- 230000003331 prothrombotic Effects 0.000 claims 1
- 150000004671 saturated fatty acids Chemical class 0.000 claims 1
- 235000003441 saturated fatty acids Nutrition 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 230000002485 urinary Effects 0.000 claims 1
Claims (16)
- 1つまたは複数の奇数鎖脂肪酸またはその医薬的に許容され得る塩、および
医薬的に許容され得るキャリア
を含む医薬組成物。 - 前記1つまたは複数の奇数鎖脂肪酸がヘプタデカン酸である、請求項1に記載の医薬組成物。
- 偶数鎖脂肪酸を実質的に含まない、請求項1〜2のいずれか一項に記載の医薬組成物。
- 複数の奇数鎖脂肪酸を含む、請求項1〜3のいずれか一項に記載の医薬組成物。
- 単位投薬形態である、請求項1〜4のいずれか一項に記載の医薬組成物。
- 1kgの体重あたり2.5mg〜11mgの前記1つまたは複数の奇数鎖脂肪酸またはその医薬的に許容され得る塩を患者に投与するために構成される、請求項1〜5のいずれか一項に記載の医薬組成物。
- 1日あたり1回の投与のために構成される、請求項1〜6のいずれか一項に記載の医薬組成物。
- 0.01mg〜10000mgの前記1つまたは複数の奇数鎖脂肪酸またはその医薬的に許容され得る塩を含む、請求項1〜7のいずれか一項に記載の医薬組成物。
- 前記1つまたは複数の奇数鎖脂肪酸が1つまたは複数の奇数鎖飽和脂肪酸である、請求項1に記載の医薬組成物。
- 代謝症候群、心臓血管疾患、糖尿病、2型糖尿病、多嚢胞性卵巣症候群、脂肪肝、コレステロール胆石、喘息、睡眠障害、ガン、腹部肥満、血圧上昇、上昇した空腹時血漿グルコース、上昇した血清トリグリセリド、低下した高密度リポタンパク質レベル、前炎症性状態、C反応性タンパク質の上昇、血栓形成促進性状態、高フェリチン血症、鉄過剰症を伴う高フェリチン血症、又は鉄過剰症を伴わない高フェリチン血症の処置または予防のための、請求項1〜9のいずれか一項に記載される医薬組成物。
- 高フェリチン血症の処置または予防のための、請求項10に記載の医薬組成物。
- 代謝症候群の処置または予防のための、請求項10に記載の医薬組成物。
- 前記医薬組成物が、代謝症候群のマーカーまたは代謝症候群の症状を調節するために構成される、請求項12に記載の医薬組成物。
- 代謝症候群の前記マーカーが、奇数鎖脂肪酸割合、奇数鎖脂肪酸の血清中濃度、奇数鎖脂肪酸の赤血球膜中濃度、血清中の総奇数鎖脂肪酸、赤血球膜中の総奇数鎖脂肪酸、血清フェリチン、血清鉄、トランスフェリチン飽和度、血清グルコース、血清トリグリセリド、血圧、アディポネクチン、HDLコレステロール、尿中微量アルブミン、CRP、IL−6、TNFα、c−Jun N末端キナーゼ、ATMおよび単球走化性タンパク質−1からなる群から選択される、請求項13に記載の医薬組成物。
- 前記医薬組成物が、前記1つまたは複数の奇数鎖脂肪酸の血清中濃度または赤血球膜中濃度を処置前の値よりも少なくとも約0.01×10−4Mだけ増大させるために構成される、請求項10〜14のいずれか一項に記載の医薬組成物。
- 1日あたり、1kgの体重あたり2.5mg〜11mgの前記医薬組成物が、前記患者に投与され、及び/又は、
前記医薬組成物が前記患者に1日あたり1回投与される、請求項10〜15のいずれか一項に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/591,660 | 2015-01-07 | ||
US14/591,660 US9561206B2 (en) | 2015-01-07 | 2015-01-07 | Use of heptadecanoic acid (C17:0) to detect risk of and treat hyperferritinemia and metabolic syndrome |
PCT/US2015/067172 WO2016111843A1 (en) | 2015-01-07 | 2015-12-21 | Compositions and methods for diagnosis and treatment of metabolic syndrome |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020002588A Division JP2020055875A (ja) | 2015-01-07 | 2020-01-10 | 代謝症候群の診断および処置のための組成物および方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018505158A JP2018505158A (ja) | 2018-02-22 |
JP2018505158A5 true JP2018505158A5 (ja) | 2019-01-24 |
JP7064879B2 JP7064879B2 (ja) | 2022-05-11 |
Family
ID=55085946
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017536879A Active JP7064879B2 (ja) | 2015-01-07 | 2015-12-21 | 代謝症候群の診断および処置のための組成物および方法 |
JP2020002588A Pending JP2020055875A (ja) | 2015-01-07 | 2020-01-10 | 代謝症候群の診断および処置のための組成物および方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020002588A Pending JP2020055875A (ja) | 2015-01-07 | 2020-01-10 | 代謝症候群の診断および処置のための組成物および方法 |
Country Status (6)
Country | Link |
---|---|
US (6) | US9561206B2 (ja) |
EP (2) | EP4410285A2 (ja) |
JP (2) | JP7064879B2 (ja) |
AR (1) | AR103371A1 (ja) |
TW (1) | TW201639557A (ja) |
WO (1) | WO2016111843A1 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10022347B2 (en) * | 2015-01-07 | 2018-07-17 | The United States Of America, As Represented By The Secretary Of The Navy | Compositions and methods for diagnosis and treatment of metabolic syndrome |
US9561206B2 (en) * | 2015-01-07 | 2017-02-07 | The United States Of America, As Represented By The Secretary Of The Navy | Use of heptadecanoic acid (C17:0) to detect risk of and treat hyperferritinemia and metabolic syndrome |
WO2018089773A1 (en) * | 2016-11-10 | 2018-05-17 | Fractyl Laboratories, Inc. | Systems, devices, and methods for performing medical procedures in the intestine |
US10307388B2 (en) * | 2016-12-29 | 2019-06-04 | The United States Of America As Represented By The Secretary Of The Navy | Compositions and methods for diagnosis and treatment of inflammation |
US10238618B2 (en) * | 2016-12-29 | 2019-03-26 | The United States Of America As Represented By The Secretary Of The Navy | Compositions and methods for diagnosis and treatment of anemia |
AU2018354090A1 (en) | 2017-10-23 | 2020-03-12 | Epitracker, Inc. | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome |
JP7492459B2 (ja) * | 2018-05-16 | 2024-05-29 | エピトラッカー インコーポレイテッド | 加齢に関連する状態の診断及び治療のための組成物及び方法 |
EP3796976A4 (en) | 2018-05-23 | 2022-03-30 | Epitracker, Inc. | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF CONDITIONS RELATED TO LONGEVITY AND QUALITY OF AGING |
CN110129400B (zh) * | 2019-05-25 | 2023-09-01 | 华南理工大学 | 一种提高微生物油脂奇数碳链脂肪酸含量的方法 |
AU2021329343A1 (en) * | 2020-08-20 | 2023-03-09 | Epitracker, Inc. | Compositions and methods for treatment of obesity |
EP4426130A1 (en) | 2021-11-03 | 2024-09-11 | Epitracker, Inc. | Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity |
CN115894217A (zh) * | 2022-10-19 | 2023-04-04 | 福建农林大学 | 一种具有降血糖作用的十七烷酸的制备与应用 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2615061A1 (de) | 1976-04-05 | 1977-10-06 | Wolfgang Dr Med Wagner | Injektionsverfahren und -vorrichtungen |
US4252159A (en) | 1979-04-02 | 1981-02-24 | Maki Eugene B | Dosage device |
JPS60172925A (ja) * | 1984-02-17 | 1985-09-06 | Kao Corp | 胆石溶解剤 |
JPS6115809A (ja) * | 1984-06-29 | 1986-01-23 | Lion Corp | 細胞賦活剤 |
DE3501534A1 (de) | 1984-09-22 | 1986-05-15 | Walter Ing.(grad.) 7758 Meersburg Holzer | Verfahren und vorrichtung zum dosieren von insulin oder aehnlichen langzeitmedikamenten |
JPS6212716A (ja) * | 1985-07-11 | 1987-01-21 | Nippon Oil & Fats Co Ltd | 制がん剤 |
DE3875075D1 (de) | 1987-11-25 | 1992-11-05 | Siemens Ag | Dosiergeraet zum gesteuerten injizieren von fluessigkeiten aus einem vorratsbehaelter in einen organismus. |
EP0569618B1 (de) | 1992-05-12 | 1997-01-02 | Siemens-Elema AB | Dosiergerät zur gesteuerten Abgabe einer Flüssigkeit |
JP3558351B2 (ja) * | 1992-12-07 | 2004-08-25 | 邦郎 辻 | 免疫抑制剤 |
AUPN137895A0 (en) * | 1995-02-27 | 1995-03-16 | Clover Corporation Pty Ltd | Composition and method |
JP2003160486A (ja) | 2001-09-17 | 2003-06-03 | Lion Corp | 経口養育毛剤及び該養育毛剤を含有する飲食品 |
US20030203042A1 (en) * | 2002-04-24 | 2003-10-30 | Cook Lisa Ann | Compositions comprising milk protein concentrate and fatty acid and processes of their preparation |
US20030203004A1 (en) | 2002-04-24 | 2003-10-30 | Kelm Gary Robert | Compositions comprising short and long chain fatty acids and methods of their use for the management of body weight |
WO2005099483A1 (en) | 2004-04-16 | 2005-10-27 | Indevex Ab | Ingestible composition |
US7651845B2 (en) | 2004-05-13 | 2010-01-26 | The Regents Of The University Of California | Method and apparatus for glucose control and insulin dosing for diabetics |
WO2005120484A1 (ja) | 2004-06-09 | 2005-12-22 | Kurume University | グレリンの生理学的機能のレギュレーター |
CA2483675A1 (en) | 2004-10-01 | 2006-04-01 | Jens Peschardt | Food bar |
US8251904B2 (en) | 2005-06-09 | 2012-08-28 | Roche Diagnostics Operations, Inc. | Device and method for insulin dosing |
JP2008255022A (ja) | 2007-04-02 | 2008-10-23 | Kureha Corp | 抗癌性物質 |
DE102007055636A1 (de) | 2007-11-21 | 2009-05-28 | Robert Bosch Gmbh | Medikamenten-Dosiervorrichtung zum Verabreichen eines flüssigen Medikaments |
US20110098358A1 (en) | 2008-06-11 | 2011-04-28 | Ricom Corporation | Human beta3 adrenergic receptor ligand, and food or pharmaceutical product containing the same |
JP2010260833A (ja) | 2009-05-11 | 2010-11-18 | Daicho Kikaku:Kk | 抗自己免疫疾患剤 |
MX348036B (es) * | 2009-12-30 | 2017-05-24 | Baylor Res Institute | Terapia anaplerótica para la enfermedad de alzheimer y el cerebro envejecido. |
US20120072236A1 (en) | 2010-08-06 | 2012-03-22 | Benjamin Atkin | Insulin pen data recording and transmission device |
GB201020133D0 (en) * | 2010-11-26 | 2011-01-12 | Royal Holloway & Bedford New College | Therapeutic use of compounds |
WO2012108954A2 (en) | 2011-02-09 | 2012-08-16 | Becton, Dickinson And Company | Nighttime basal dosing device |
ITMI20111284A1 (it) * | 2011-07-11 | 2013-01-12 | Giovanni Nusca | Composizione farmaceutica. |
EP3217879B1 (en) * | 2014-11-11 | 2020-01-08 | Koninklijke Philips N.V. | Source-detector arrangement |
US9561206B2 (en) * | 2015-01-07 | 2017-02-07 | The United States Of America, As Represented By The Secretary Of The Navy | Use of heptadecanoic acid (C17:0) to detect risk of and treat hyperferritinemia and metabolic syndrome |
US9662306B2 (en) * | 2015-01-07 | 2017-05-30 | The United States Of America, As Represented By The Secretary Of The Navy | Compositions and methods for diagnosis and treatment of metabolic syndrome |
US10022347B2 (en) * | 2015-01-07 | 2018-07-17 | The United States Of America, As Represented By The Secretary Of The Navy | Compositions and methods for diagnosis and treatment of metabolic syndrome |
US10307388B2 (en) | 2016-12-29 | 2019-06-04 | The United States Of America As Represented By The Secretary Of The Navy | Compositions and methods for diagnosis and treatment of inflammation |
US10238618B2 (en) | 2016-12-29 | 2019-03-26 | The United States Of America As Represented By The Secretary Of The Navy | Compositions and methods for diagnosis and treatment of anemia |
JP7001554B2 (ja) * | 2018-06-27 | 2022-01-19 | ヤンマーパワーテクノロジー株式会社 | クレーン機能付き油圧ショベル |
-
2015
- 2015-01-07 US US14/591,660 patent/US9561206B2/en active Active
- 2015-12-21 JP JP2017536879A patent/JP7064879B2/ja active Active
- 2015-12-21 EP EP24161769.5A patent/EP4410285A2/en active Pending
- 2015-12-21 WO PCT/US2015/067172 patent/WO2016111843A1/en active Application Filing
- 2015-12-21 EP EP15823481.5A patent/EP3247346B1/en active Active
- 2015-12-28 US US14/981,130 patent/US9713600B2/en active Active
- 2015-12-28 US US14/980,167 patent/US20160195558A1/en not_active Abandoned
- 2015-12-28 US US14/980,695 patent/US9687461B2/en active Active
- 2015-12-28 US US14/980,304 patent/US9707199B2/en active Active
-
2016
- 2016-01-06 TW TW105100321A patent/TW201639557A/zh unknown
- 2016-01-06 AR ARP160100021A patent/AR103371A1/es unknown
-
2019
- 2019-08-07 US US16/534,382 patent/US11116740B2/en active Active
-
2020
- 2020-01-10 JP JP2020002588A patent/JP2020055875A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018505158A5 (ja) | ||
Wu et al. | Pseudoephedrine/ephedrine shows potent anti-inflammatory activity against TNF-α-mediated acute liver failure induced by lipopolysaccharide/d-galactosamine | |
HRP20192291T1 (hr) | Bardoksolon-metil, namijenjen liječenju pretilosti | |
Parlevliet et al. | GLP-1 treatment reduces endogenous insulin resistance via activation of central GLP-1 receptors in mice fed a high-fat diet | |
JP2013509429A5 (ja) | ||
RU2018133298A (ru) | Способы применения агонистов fxr | |
FI2981255T3 (fi) | Empagliflotsiinin terapeuttiset käytöt | |
JP2009215293A5 (ja) | ||
JP2015503593A5 (ja) | ||
JP2015518818A5 (ja) | ||
JP2020502156A5 (ja) | ||
AR103371A1 (es) | Composiciones y métodos para diagnosis y tratamiento de síndrome metabólico, uso | |
RU2018136872A (ru) | Композиции, содержащие 15-oh эпк, и способы их применения | |
JP2010515682A5 (ja) | ||
JP2017519028A5 (ja) | ||
RU2018140900A (ru) | Семаглутид при сердечно-сосудистых состояниях | |
JP2017014206A5 (ja) | ||
JP2014533701A5 (ja) | ||
JP2015514797A5 (ja) | ||
RU2015127834A (ru) | Способы лечения диабета путем введения антагониста рецептора глюкагона в сочетании с ингибитором поглощения холестерина | |
JP2011157375A5 (ja) | ||
JP2013501049A5 (ja) | ||
JP2017512194A5 (ja) | ||
JP2015501832A5 (ja) | ||
Elahi et al. | Long-term statin administration to dams on high-fat diet protects not only them but also their offspring from cardiovascular risk |